Market Cap 7.34M
Revenue (ttm) 1.02M
Net Income (ttm) -10.36M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,015.69%
Debt to Equity Ratio 0.12
Volume 43,600
Avg Vol 50,420
Day's Range N/A - N/A
Shares Out 4.32M
Stochastic %K 86%
Beta 0.63
Analysts Sell
Price Target $11.00

Company Profile

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. The company offers monolithic solid silicon nitride; solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyether ether ketone, and Polyether Ether Ketone (P...

Industry: Medical Devices
Sector: Healthcare
Phone: 801 839 3500
Address:
1885 West 2100 South, Salt Lake City, United States
Boston7452
Boston7452 Jul. 31 at 6:11 PM
$SINT I’d take this one step further. Sintx has spent 25 years engineering the single most advanced and critical biomaterial in medical science at just the right time. Its dual nature as both antiinfective and growth stimulating is what makes it a medical marvel. It defends against infection of plants and animals while at the same time helping those plants and animals grow and heal faster.
1 · Reply
Boston7452
Boston7452 Jul. 29 at 9:41 PM
$SINT 👋
0 · Reply
Boston7452
Boston7452 Jul. 29 at 4:59 PM
$SINT Some details from a retrospective study out of Australia i founds years ago.
1 · Reply
Boston7452
Boston7452 Jul. 28 at 8:34 PM
$SINT Needs to form a Next Gen Biotech subsidiary
0 · Reply
Boston7452
Boston7452 Jul. 28 at 7:23 PM
$SINT Then theres the next gen products Sintx material can be used in. For example: Bio-Synthetic Artificial Organs: Silicon Nitride can be machined into highly complex, porous, 3D-printed scaffolds. Because it resists both bacterial biofilm colonization and thrombosis (blood clotting), it provides a foundation for the next generation of artificial hearts, kidney dialysis membranes, and synthetic livers.
0 · Reply
Boston7452
Boston7452 Jul. 28 at 7:16 PM
$SINT They could use this to help fight Ebola... "Integrating SINTX's FleX-SN AP powder into hospital privacy curtains, bedsheets, scrubs, wall paints, and air filters turns the entire clinical environment into a passive "catch-and-kill" zone"
0 · Reply
Boston7452
Boston7452 Jul. 28 at 5:32 PM
$SINT This is Sintx Si3N4 single biggest appeal to hospitals: "all unified under a single, proprietary "SINTX Inside" antimicrobial guarantee that reduces hospital readmission penalties." I criticize management for their execution over the years but my best guess is they have been trying to guard the tech while executing this larger plan. However the way they went about guarding this tech stole alot of money from anyone, including me, who could see its benefit. There has to be a better way to protect the IP and the people who want to be part of something as TRUELY transformative as Sintx material and patented moat. Sintx true underlying story buried behind layers of shit is "Sintx Inside" and what that truly translates into for the global medical industry.
1 · Reply
Boston7452
Boston7452 Jul. 28 at 5:11 PM
$SINT "For activist investors or corporate development teams evaluating the deal, SINTX's market cap sits at a fraction of its intellectual property's true vertical value"
1 · Reply
Boston7452
Boston7452 Jul. 28 at 3:44 PM
$SINT Revised value matrix breaking down upfronts by the 7 uses and how quick to market. Tiers 1 & 2 are quickest (9-15months) with tier 3 being longest (3-5 years) and most comprehensive not to mention the most valuable tier. Google thinks Varian may insist on holding 30% of the upfront value in escrow until trials begin for tier 3. If Southern Metric negotiates this sort of deal as it should, Sintx would not likely have to tap the markets again. Especially if it transitions to more of a royalty & licensing house instead of real OEM manufacturer. Which it could with the coating patent, antipathogenic patent, and base material patents.
0 · Reply
focafoca99
focafoca99 Jul. 28 at 1:10 PM
$SINT preview its Q2 2026 earnings release on Aug 11 after market close, with a 4:30 p.m. ET webcast. https://www.rapidticker.com/news/sint-sintx-technologies-announces-second-quarter-cae8f7
0 · Reply
Latest News on SINT
Sintx Technologies Registration statement: Registration filing

Jun 25, 2026, 8:00 AM EDT - 5 weeks ago

Sintx Technologies Registration statement: Registration filing


Sintx Technologies receives $3.2M in purchase orders

2026-06-22T14:00:56.000Z - 6 weeks ago

Sintx Technologies receives $3.2M in purchase orders


Sintx Technologies Transcript: Transcript

Jun 15, 2026, 11:13 AM EDT - 7 weeks ago

Sintx Technologies Transcript: Transcript


Sintx Technologies resumed with a Buy at Maxim

2026-06-04T11:45:10.000Z - 2 months ago

Sintx Technologies resumed with a Buy at Maxim


Sintx Technologies initiated with a Buy at H.C. Wainwright

2026-04-13T10:11:23.000Z - 4 months ago

Sintx Technologies initiated with a Buy at H.C. Wainwright


Sintx Technologies appoints Elmore as President

2026-02-18T13:40:31.000Z - 5 months ago

Sintx Technologies appoints Elmore as President


Sintx Technologies signs supply agreement with EVONIK

2025-12-01T13:35:45.000Z - 8 months ago

Sintx Technologies signs supply agreement with EVONIK


Sintx Technologies reports Q3 EPS ($3.46) vs ($6.96) last year

2025-11-13T13:05:19.000Z - 9 months ago

Sintx Technologies reports Q3 EPS ($3.46) vs ($6.96) last year


Sintx Technologies Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Sintx Technologies Earnings release: Q3 2025


Sintx Technologies announces launch of OsseoSculpt

2025-11-03T13:05:41.000Z - 9 months ago

Sintx Technologies announces launch of OsseoSculpt


Sintx Technologies announces U.S. patent notice of allowance

2025-10-14T11:11:00.000Z - 10 months ago

Sintx Technologies announces U.S. patent notice of allowance


Why Is Sintx Technologies Stock (SINT) Down 20% Today?

2025-09-09T02:54:00.000Z - 11 months ago

Why Is Sintx Technologies Stock (SINT) Down 20% Today?


Sintx Technologies receives USPTO notice of allowance

2025-09-08T11:25:37.000Z - 11 months ago

Sintx Technologies receives USPTO notice of allowance


Sintx Technologies Earnings release: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

Sintx Technologies Earnings release: Q1 2025


SINTX Technologies Announces Stock Repurchase Program

Nov 18, 2024, 6:00 AM EST - 1 year ago

SINTX Technologies Announces Stock Repurchase Program


SINTX Technologies to Explore Strategic Opportunities

Jun 18, 2024, 9:00 AM EDT - 2 years ago

SINTX Technologies to Explore Strategic Opportunities


Boston7452
Boston7452 Jul. 31 at 6:11 PM
$SINT I’d take this one step further. Sintx has spent 25 years engineering the single most advanced and critical biomaterial in medical science at just the right time. Its dual nature as both antiinfective and growth stimulating is what makes it a medical marvel. It defends against infection of plants and animals while at the same time helping those plants and animals grow and heal faster.
1 · Reply
Boston7452
Boston7452 Jul. 29 at 9:41 PM
$SINT 👋
0 · Reply
Boston7452
Boston7452 Jul. 29 at 4:59 PM
$SINT Some details from a retrospective study out of Australia i founds years ago.
1 · Reply
Boston7452
Boston7452 Jul. 28 at 8:34 PM
$SINT Needs to form a Next Gen Biotech subsidiary
0 · Reply
Boston7452
Boston7452 Jul. 28 at 7:23 PM
$SINT Then theres the next gen products Sintx material can be used in. For example: Bio-Synthetic Artificial Organs: Silicon Nitride can be machined into highly complex, porous, 3D-printed scaffolds. Because it resists both bacterial biofilm colonization and thrombosis (blood clotting), it provides a foundation for the next generation of artificial hearts, kidney dialysis membranes, and synthetic livers.
0 · Reply
Boston7452
Boston7452 Jul. 28 at 7:16 PM
$SINT They could use this to help fight Ebola... "Integrating SINTX's FleX-SN AP powder into hospital privacy curtains, bedsheets, scrubs, wall paints, and air filters turns the entire clinical environment into a passive "catch-and-kill" zone"
0 · Reply
Boston7452
Boston7452 Jul. 28 at 5:32 PM
$SINT This is Sintx Si3N4 single biggest appeal to hospitals: "all unified under a single, proprietary "SINTX Inside" antimicrobial guarantee that reduces hospital readmission penalties." I criticize management for their execution over the years but my best guess is they have been trying to guard the tech while executing this larger plan. However the way they went about guarding this tech stole alot of money from anyone, including me, who could see its benefit. There has to be a better way to protect the IP and the people who want to be part of something as TRUELY transformative as Sintx material and patented moat. Sintx true underlying story buried behind layers of shit is "Sintx Inside" and what that truly translates into for the global medical industry.
1 · Reply
Boston7452
Boston7452 Jul. 28 at 5:11 PM
$SINT "For activist investors or corporate development teams evaluating the deal, SINTX's market cap sits at a fraction of its intellectual property's true vertical value"
1 · Reply
Boston7452
Boston7452 Jul. 28 at 3:44 PM
$SINT Revised value matrix breaking down upfronts by the 7 uses and how quick to market. Tiers 1 & 2 are quickest (9-15months) with tier 3 being longest (3-5 years) and most comprehensive not to mention the most valuable tier. Google thinks Varian may insist on holding 30% of the upfront value in escrow until trials begin for tier 3. If Southern Metric negotiates this sort of deal as it should, Sintx would not likely have to tap the markets again. Especially if it transitions to more of a royalty & licensing house instead of real OEM manufacturer. Which it could with the coating patent, antipathogenic patent, and base material patents.
0 · Reply
focafoca99
focafoca99 Jul. 28 at 1:10 PM
$SINT preview its Q2 2026 earnings release on Aug 11 after market close, with a 4:30 p.m. ET webcast. https://www.rapidticker.com/news/sint-sintx-technologies-announces-second-quarter-cae8f7
0 · Reply
Boston7452
Boston7452 Jul. 27 at 6:06 PM
$SINT what grounds? Price manipulation/suppression via the February 19th, 2025 press release. There’s more than just this but that one’s easy to expose. Significant patent received that allows for quick to market coating of all current inventory if a company wanted to instill the benefits of Si3N4 to their currently cleared device. Total time to market is 2-4 months based on how quickly FDa reviews and how quickly inventory is modified. That patent was hidden behind a headline of an ancillary patent they already received in December 2024.
1 · Reply
Boston7452
Boston7452 Jul. 27 at 2:34 AM
$SINT now one thing Sintx management may do, especially if they want to try to take this private/sell cheap, is continue to weaken Sintx position and drag out negotiations leading to more shares being released new offerings. If you’re a shareholder like me consider contacting the SEC. We may need them to remove Sintx board and management /invalidate June warrants and auction the IP to the likes of Varian, Zimmer Biomet, Solventum, and Fisher.
0 · Reply
Boston7452
Boston7452 Jul. 26 at 8:55 PM
$SINT If Sintx does a direct contract with Varian, the preferred method, Sintx could receive 15-30m direct tech transfer fee in addition to the aforementioned 30-60m upfronts for each device use. Google indicates that part of that 30-60m, roughly 30%, maybe locked in an escrow account until trials for use 3 begins. Its royalty percentages would be lower but it would make more per device based on the price Varian sells to the Hospital. Thats before factoring its cost + 50-100% manufacturing revenue.
1 · Reply
Boston7452
Boston7452 Jul. 26 at 6:45 PM
$SINT These numbers are liver cancers to start. As Ned and/or Varian expand their targeted organs, these numbers only grow.
2 · Reply
Boston7452
Boston7452 Jul. 26 at 6:13 PM
$SINT While Google may have given me total Combisphere information originally, because Combisphere's 7 use platform cannot exist without Sintx Silicon Nitride, the new valuation matrix is closer to the numbers i originally gave.
3 · Reply
Boston7452
Boston7452 Jul. 26 at 5:19 PM
$SINT I need to fix this. Google was giving me the information based on if Sintx had combisphere commcerialization rights, thats Ned Medical. Also the upfront payment that I originally presented is incorrect due to the 7 combinations. The total upfront to Ned Medical should be 90-175m with Sintx or 10-25m upfront from Ned. Sintx should receive Cost + margins of 40-60% and royalties of 2-4% with milestone payments of 2-5m per FDA clearance.
3 · Reply
Boston7452
Boston7452 Jul. 26 at 2:45 PM
$SINT Varians in the position to kick all that off so let’s get that moving. According to Google AI analysis, Varian can justify paying 40-90m upfront because Combisphere is not a one trick pony but a 3 tiered device that can begin bringing in revenue within a year with a 2nd product a little over a year. Thus Sintx could receive royalties of 5-15% in a tiered fashion as each device is cleared for market. Tier 1 : 5-7% Tier2: 8-11% Tier 3: 12-15%
3 · Reply
Boston7452
Boston7452 Jul. 26 at 12:36 AM
$SINT 5 pillars of Sintx IP across 4 conglomerates.
2 · Reply
Boston7452
Boston7452 Jul. 25 at 11:50 PM
$SINT This is layer 2 of Sintx very valuable IP, The Anti pathogenic Patent from October 2025. This presents greater value than the coating in Sintx IP valuation. Both the coating and AP patents are more valuable than the IP Varian is examining for Oncology purposes.
0 · Reply
Boston7452
Boston7452 Jul. 25 at 10:43 PM
$SINT "SINTX or its device partners qualify for the Special 510(k) pathway. The 30-Day Clock: Because a manufacturer is modifying their own legally marketed device, the FDA aims to review Special 510(k) submissions within 30 days. This is the fastest review cycle available for Class II devices" "The regulatory path is highly predictable because the implant's structural foundation is already cleared. Financially, while the technical laser processing adds a per-unit cost, it yields an incredibly high return by bypassing the years of R&D and manufacturing capital required to launch an entirely new implant line from scratch"
0 · Reply
Boston7452
Boston7452 Jul. 25 at 10:31 PM
$SINT Good Example of that billion dollar, or really multi-billion dollar IP while the stock price was suppressed.
0 · Reply
Boston7452
Boston7452 Jul. 24 at 9:52 PM
$SINT management has done a really good job creating value. IP is worth billions. While at the same time they’ve done quite well at price suppression. Go figure.
0 · Reply